Agitated Solutions Enrolls First Patient in Phase 3 ‘ENHANCE’ Trial of Novel Contrast Agent for Cardiac Bubble Studies
First patient has been enrolled at Northwestern University by cardiologist Akhil Narang, M.D. The data we collect from this trial will support the safety and effectiveness of our novel, right-heart contrast agent and build on our early commercial experience in Canada.” — Morgan Evans, CEO, Agitated Solutions, Inc. ST. PAUL, MN, UNITED STATES, November 6,…
